Special Update -Â PCYC â Imbruvicaâs Flies To Blockbuster Status; Solid Tumor/I-O Potential Even Larger â Raising TARGET PRICE â At the JPM presentation, PCYC surprised everyone with guidance for Imbruvica sales. The Company, one of the most conservative with regards to public forecasts, had not previously provided any number with regards to Imbruvica sales. Moreover,[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.